Currently, the clinical efficiency of PD‐1/PD‐L1 inhibitors are widely estimated in various cancer types31 and we collected a GBM cohort of total 14 participants who accepted PD‐1 inhibitors treatment to investigate the association between SLC12A5 and immunotherapy response. This evidence concerns the gene SLC12A5 and glioblastoma.